

Ellenoff Grossman & Schole LLP

2019 Representative Underwritten Offering Transactions

Areas of Practice Include:

CORPORATE AND
SECURITIES

PUBLIC OFFERING

PRIVATE EQUITY/
VENTURE CAPITAL

MERGERS AND
ACQUISITIONS

PRIVATE
INVESTMENT FUNDS

REAL ESTATE
DEVELOPMENT &
FINANCE

COMMERCIAL LEASING

BROKER-DEALER
REGULATION

INTERNATIONAL AND
DOMESTIC TAX

McEwen Mining Inc.

(NYSE:MUX)

\$50,019,316

**Cantor Fitzgerald and
Roth Capital Partners**

acted as joint book-running managers
in connection with the offering

November 22, 2019

EG&S acted as counsel to the Underwriter

Cellular Biomedicine Group, Inc.

(NASDAQ:CBMG)

\$17,500,000

**Cantor Fitzgerald & Co. and
Robert W. Baird & Co.**

acted as joint book-running managers
in connection with the offering

March 21, 2019

EG&S acted as counsel to Cellular Biomedicine

Pulmatrix, Inc.

(NASDAQ:PULM)

\$16,559,997

H.C. Wainwright & Co.

acted as sole book-running manager
in connection with the offering

April 8, 2019

EG&S acted as counsel to the Underwriter

Plus Therapeutics, Inc.

(NASDAQ:PSTV)

\$14,999,793

H.C. Wainwright & Co.

acted as sole book-running manager
in connection with the offering

September 25, 2019

EG&S acted as counsel to the Underwriter

CHF Solutions, Inc.

(NASDAQ:CHFS)

\$11,426,398

Ladenburg Thalmann & Co. Inc.

acted as the sole book-running manager
in connection with the offering

March 12, 2019

EG&S acted as counsel to the Underwriter

Viveve Medical, Inc.

(NASDAQ:VIVE)

\$10,469,997

Ladenburg Thalmann & Co. Inc.

acted as the sole book-running manager
in connection with the offering

November 26, 2019

EG&S acted as counsel to the Underwriter

Ellenoff Grossman & Schole LLP

2019 Representative Underwritten Offering Transactions

Areas of Practice Include:

CORPORATE AND
SECURITIES

PUBLIC OFFERING

PRIVATE EQUITY/
VENTURE CAPITAL

MERGERS AND
ACQUISITIONS

PRIVATE
INVESTMENT FUNDS

REAL ESTATE
DEVELOPMENT &
FINANCE

COMMERCIAL LEASING

BROKER-DEALER
REGULATION

INTERNATIONAL AND
DOMESTIC TAX

Cerecor Inc. (NASDAQ:CERC)

\$10,000,000

H.C. Wainwright & Co.

acted as the sole book-running manager
in connection with the offering

March 8, 2019

EG&S acted as counsel to the Underwriter

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)

\$9,200,000

Maxim Group LLC

acted as the sole book-running manager
in connection with the offering

February 26, 2019

EG&S acted as counsel to Maxim Group LLC

ImmuCell Corporation (NASDAQ:ICCC)

\$9,000,002

Craig-Hallum Capital Group

acted as sole book-running manager
in connection with the offering

March 29, 2019

EG&S acted as counsel to the Underwriter

Artelo Biosciences, Inc. (NASDAQ:ARTL)

\$8,000,000

Maxim Group LLC

acted as sole book-running manager
in connection with the offering

June 25, 2019

EG&S acted as counsel to Maxim Group LLC

AquaBounty Technologies, Inc. (NASDAQ:XON)

\$7,526,884

H.C. Wainwright & Co.

acted as the sole book-running manager
in connection with the offering

March 21, 2019

EG&S acted as counsel to the Underwriter

Neuralstem, Inc. (NASDAQ:CUR)

\$7,499,819

H.C. Wainwright & Co.

acted as the sole book-running manager
in connection with the offering

July 30, 2019

EG&S acted as counsel to the Underwriter

Ellenoff Grossman & Schole LLP

2019 Representative Underwritten Offering Transactions

Areas of Practice Include:

CORPORATE AND
SECURITIES

PUBLIC OFFERING

PRIVATE EQUITY/
VENTURE CAPITAL

MERGERS AND
ACQUISITIONS

PRIVATE
INVESTMENT FUNDS

REAL ESTATE
DEVELOPMENT &
FINANCE

COMMERCIAL LEASING

BROKER-DEALER
REGULATION

INTERNATIONAL AND
DOMESTIC TAX

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI)

\$6,800,000

Maxim Group LLC

acted as the sole book-running manager
in connection with the offering

August 14, 2019

EG&S acted as counsel to Maxim Group LLC

AquaBounty Technologies, Inc. (NASDAQ:AQB)

\$5,747,827

H.C. Wainwright & Co.

acted as the sole book-running manager
in connection with the offering

April 19, 2019

EG&S acted as counsel to the Underwriter

Dare Bioscience, Inc. (NASDAQ:DARE)

\$5,032,500

Roth Capital Partners

acted as sole book-running manager
in connection with the offering

April 11, 2019

EG&S acted as counsel to the Underwriter

AzurRx BioPharma (NASDAQ:AZRX)

\$5,000,000

H.C. Wainwright & Co.

acted as sole book-running manager
in connection with the offering

July 22, 2019

EG&S acted as counsel to the Underwriter

Neovasc Inc. (NASDAQ:NVCN)

\$5,000,000

H.C. Wainwright & Co.

acted as the sole book-running manager
in connection with the offering

February 28, 2019

EG&S acted as counsel to the Underwriter

Yield10 Bioscience, Inc. (NASDAQ:YTEN)

\$4,999,750

Ladenburg Thalmann & Co.

acted as the sole book-running manager
in connection with the offering

November 19, 2019

EG&S acted as counsel to the Underwriter